Essink, B. J., Shapiro, C., Isidro, M. G. D., Bradley, P., Pragalos, A., Bloch, M., . . . Vanhoutte, N. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study. Taylor & Francis Group.
Chicago Style (17th ed.) CitationEssink, Brandon J., et al. Safety and Immunogenicity of a Modified MRNA-lipid Nanoparticle Vaccine Candidate Against COVID-19: Results from a Phase 1, Dose-escalation Study. Taylor & Francis Group.
MLA (9th ed.) CitationEssink, Brandon J., et al. Safety and Immunogenicity of a Modified MRNA-lipid Nanoparticle Vaccine Candidate Against COVID-19: Results from a Phase 1, Dose-escalation Study. Taylor & Francis Group.
Warning: These citations may not always be 100% accurate.